The effect of gabapentin and the combination of gabapentin and montelukast on cough in Covid-19 patients
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20150721023282N24
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 185
Inclusion Criteria
Age over 18 years
Infection of Covid-19 with any severity with the criteria of pulmonary involvement in lung CT scan with positive test RT PCR Covid-19
BCSS score higher than 2
Oral intake (PO) tolerance
Exclusion Criteria
mechanical ventilation
Allergy to drugs
Loss of consciousness
discharge earlier than 6 days
Chronic underlying and allergic lung disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cough severity. Timepoint: Before and after the intervention. Method of measurement: VAS (Visual analog scale).
- Secondary Outcome Measures
Name Time Method